References
- Brander A, Viikinkoski P, Nickels J, Kivisaari L. Thyroid gland: US screening in a random adult population. Radiology181(3), 683–687 (1991).
- Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA295(18), 2164–2167 (2006).
- Kang HW, No JH, Chung JH et al. Prevalence, clinical and ultrasonographic characteristics of thyroid incidentalomas. Thyroid14(1), 29–33 (2004).
- Frates MC, Benson CB, Doubilet PM et al. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J. Clin. Endocrinol. Metab.91(9), 3411–3417 (2006).
- Mazzaferri EL. Management of a solitary thyroid nodule. N. Engl. J. Med.328(8), 553–559 (1993).
- Shaha AR, Tuttle RM, Shah JP. Papillary microcarcinoma of the thyroid. J. Surg. Oncol.95(7), 532–533 (2007).
- DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab.71(2), 414–424 (1990).
- Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer83(12), 2638–2648 (1998).
- Mazzaferri EL. Managing small thyroid cancers. JAMA295(18), 2179–2182 (2006).
- Cooper DS, Doherty GM, Haugen BR et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid16(2), 109–142 (2006).
- Fliegelman LJ, Genden EM, Brandwein M, Mechanick J, Urken ML. Significance and management of thyroid lesions in lymph nodes as an incidental finding during neck dissection. Head Neck23(10), 885–891 (2001).
- Antonaci A, Anello A, Aucello A et al. Microcarcinoma and incidental carcinoma of the thyroid in a clinical series: clinical behaviour and surgical management. Clin. Ter.157(3), 225–229 (2006).
- Cappelli C, Castellano M, Braga M et al. Aggressiveness and outcome of papillary thyroid carcinoma (PTC) versus microcarcinoma (PMC): a mono-institutional experience. J. Surg. Oncol.95(7), 555–560 (2007).
- Mazzaferri EL, Young RL, Oertel JE, Kemmerer WT, Page CP. Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine (Baltimore)56(3), 171–196 (1977).
- Hay ID. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J. Surg. Oncol.94(8), 692–700 (2006).
- Sawka AM, Brierley JD, Tsang RW et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol. Metab. Clin. North Am.37(2), 457–480 (2008).
- Mazzaferri E. A randomized trial of remnant ablation – in search of an impossible dream? J. Clin. Endocrinol. Metab.89(8), 3662–3664 (2004).
- Ito Y, Uruno T, Nakano K et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid13(4), 381–387 (2003).
- Tuttle RM, Leboeuf R, Robbins RJ et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J. Nucl. Med.47(10), 1587–1591 (2006).
- Rubino C, de Vathaire F, Dottorini ME et al. Second primary malignancies in thyroid cancer patients. Br. J. Cancer89(9), 1638–1644 (2003).
- Mazzaferri EL. Management of low-risk differentiated thyroid cancer. Endocr. Pract.13(5), 498–512 (2007).
- Shattuck TM, Westra WH, Ladenson PW, Arnold A. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N. Engl. J. Med.352(23), 2406–2412 (2005).
- Puxeddu E, Durante C, Avenia N, Filetti S, Russo D. Clinical implications of BRAF mutation in thyroid carcinoma. Trends Endocrinol. Metab.19(4), 138–145 (2008).
- Mechanick JI, Carpi A. Thyroid cancer: the impact of emerging technologies on clinical practice guidelines. Biomed. Pharmacother.62(8), 554–558 (2008).